Abstraa. Scnm Kpo-proteins were measured over a jjcriod of fi riKRitlis in H oophorectomised women ireate<l with oestrogen implants (50 rag oestradiol-lTp) and 17 oophorectomised women treated with oestrogen/ tcsiosicrone impJants (50 mg oestradiol-17p, 100 mg testosterone). B<«!i types ofimplant caused only minima! clianges in lipjprotcjn nK'tabolism. I/jw density lipoprotein (IX>I.) cholesterol decreased with both types of implant and high density lipoprotein (HDL} cholesterol rose with the oesirtigcn implaivt-s. HDLsubfractions were al.>;o measured. The tiestrogen implants caused a tran-.sienl rise in HDI^ clMilcstcrol !c-vels at 2 months and a slower rise ill HDLj cholesterol. The oestrogen/testosterone implants had no effect on HOI, fractions. The results indioilo that hormone implants do not cause the profound chanjfcs in lipoproteins associated with oral hormone therapy. Patients and Methods liTurty-one women attending menopausal clinics at the Western Infirmary and Stobhiil Hospital. Glasgow who were suffering from dimaaeric symptoms were treated with hormone implants. They were aged between 36 and 54 years (mean age 46,4 years) and all had undergone hysterectomy and bilateral oophorectomy for non-inalgSnant conditions. At least 6 weeks had elapsed post-C)pQfiici0n prior to •cotBinencing, treattnem and informed, consent was obtained in all cases before implant insertion. None of the women had receK'ed any hormone therapy prior to commencing treatment nor were taking any drug liable to interfere with lipid metabolism. None 116
.
(X'Strogcii.s, whcu administered orally have been shown to CHI we .sigtiificant alterations in lipoproteins (Tikkancn cl ; d-1978; Silfverstolpe et aL 1980) . However, Fahraeiis et al. (1982) found that the changes in lipoproteins caused by oestradioli7p titken orally were not in evidence when it was administered as a cream and Buckraan et al. (1980) found that parenteral depo-ocstradiol cypionate had little effect on serum lipoproteins. To date there has only been one detailed report; dealing wth the effects on lipoproteins of oestrogens administered as a subcutaneous (sc) implant. Brook et al. (1982) studied 3 women for a period of 12 weeks and noted profound changes in serum lipoproteins, particularly in high density lipoprotein (WBL) and its subclasses.
In this study we describe changes in lipoprotein.s over a period of 6 months in 31 oophorectomised women who were receiviiig hormone replacement therapy by way of sc implants. Two types of implant were used, one containing only oestradiol17p, the other an oestradiol/testosterone mixture, since it has been suggested (Studd et al. 197^ ) ihM the inclusion of testosterone improves libido in postmenopaasal women.
Patients and Methods liTurty-one women attending menopausal clinics at the Western Infirmary and Stobhiil Hospital. Glasgow who were suffering from dimaaeric symptoms were treated with hormone implants. They were aged between 36 and 54 years (mean age 46,4 years) and all had undergone hysterectomy and bilateral oophorectomy for non-inalgSnant conditions. At least 6 weeks had elapsed post-C)pQfiici0n prior to •cotBinencing, treattnem and informed, consent was obtained in all cases before implant insertion. None of the women had receK'ed any hormone therapy prior to commencing treatment nor were taking any drug liable to interfere with lipid metabolism. None
•mie I.
Oestradiol and testosterone levels (mean ± SEM) in postmenopausal women treated with hormone implants. * Ten tvoraen had oestradiol levels less than 100 pmol/1. The other 4 had levels less than 200 pmol/1. ** Twelve women had oe.stradiol levels less than 100 pmol/1. The other 5 had levels less than 175 pmol/l. of the women had renal or hepadc abnormalities before or during treatment as indicated by routine biochemical tests.
The women were randomly divided into two groups. Fourteen women were given oestrogen implants (50 mg oestradioH7P) and the remaining 17 were given oestrogen/testosterone implants (56 mg oe.s'tradioI-'17p. TOO mgtestosterone).
Blood was obtained, after a 14 h fast, prior to insertion of the implant and 2,4 and 6 months post implantation. Serum was separated by centrifuging at 1000 X g for J 0 min at A'C. An aliquot of serum was stored at 4°C for a maximum of 5 days prior to lipoprotein analysis and a further aliquot storedat -J20°C for steroid anai)'sis.
Serum lipoproteins were separated into their density classes by ttltracentrifugadon (Airfuge, Beckman Instruments Ltd., High Wycombe, England) as previously described (Parish ctal. 1983 ). In addition, total HDLand HDI, subfractions were measured in 10 of the women who had oestrogen implants and 9 who had oestrogen/ testosterone implants using the meAod described by Eyre et al. (1981) . Cholesterol concentrations were estimated manually using an enzymatic technique (AlJain et al, 1974) . Total serum triglyceride concentrations were also quantitated enzymatically (Bucolo & David 197S) using a Gemini centrifugal analyser (Electro-Neucleonics (nc. Breda, The Netherlands).
'Sevam o«£ft'aj6l -was ^femUYtd by a radioimmtinoassay (RI A) which used a rabbit antiserum raised against oestrad)ol-6-0-carhoxymethyloxime-BSA, pH]oestradiol and a double antibody separation. The sensitivity of the system was 100 pmol/1 and the inter-assay CV was 11%. Serum testosterone -was also measured by RIA using a tlouble antibody system employing a rabbit antiserum raised against teswsterOM-S-O-carboxytnethyl^xime-BSA and an ['"Ijhistamine conjugate of testosterone-3-O-carboxymethyloxime as radioligand. The assay had a sensitivity of OS tmiol/l and an inter-assay precirion of 10%.
The results obtained were analysed by standard statistical techniques. Lilliefors' test (Conover 1975 ) was used to ascertain whether the sample data were normally Lipoprotein levels (mean ± .?D) in postmenopausal women treated with oestrogen-only implants. •Results
Oestradiol and testosterone levels for the 31 woincji are shown in Table 1 . In both groups (jesiradiol levels rose in the first 2 momhs to prc-mcnopattsal levels at which ihcy remained for the rest of the trial, 'i'estostefotie levek remained constant in the ocstrogcii-onty group for the whfjie of the (5 months. In the <5estrogen/testt).'!teronc group, ihey rose hi the first 2 monih.s then gradually fell to pre-trcalmcni levdsat fi month,s. cholesterol. The only significant change caused by the oestradiolAestosterone implant.s was a reduction in I-DL levels. Table 4 shows total HDL, HDl.z and HDL,i levels for 10 of the women who had oestrogen hnplants.
There i^'as a ttmponfry elevation of HDi.i cholesterol levels at 2 months and a .slower but more sustained increase in HDLj cholesterol levels. The levels of total HDL and the HD!. subfractions were unaffeaed by the oestrogen/te.stosterone implants (Table 5) .
Discussion
Oral natui-il oestrogens have l>een shown to elevate HDL cholesterol levels and reduce LDL cholesterol levels (Tikkanen et al. 1978; Silfi-erstolpc We have shown that implants do not produce the profound alterations in serum lipids produced by oral therapy. The o'rtly significant alterations, were the lowering of LDL cholesterol by both types of implant and the incTcasing of HDL cholesterol by the oestrogen implants and none of these change.? were large. Fahraeus et al. (1982) investigating the effects of parenteral oestradiol-17p, produced similar results in that they found a gradual decrease in LDL cholesterol levels. However, they found no changes in HDLcholesteirtl levels.
The effects of natural oestrogens and androgens on HDL subfractions are not well documented. Brook et al. (1982) reported oestradioi-I7p implants caused marked increases in both HDLi and HQLa cholesteXQl Q.v?fperiodof 3 months. This contrasts with our finding of small increases in HDL subfractions. However, Brook et al. (1982) studied only 3 women and used implants containing double the amount of oestradiol-173 used in the present study. We found the addition of testosterone to the implants to have only a slight effea on the HDL stlbfi-action changes, preventing the small rises produced by oestrogen alone.
It is not as yet dear why parenteral oestrogen therapy should differ so markedly from oral therapy in its effects since the oestradiol levels we found with the implants were comparable to those produced by oral therapy (Lind et al. 1979) . A likely explanation eked by previous workers (Buckman et al-1980; Fahraeus et al. 1982 ) is that oral oe.'itrogeiis lead to peaks in intrahepatic and plasma concentrations and these cause the marked changes in lipoprotein levels.
In a recent study carried out on a similar group of bilaterally oophorectomised women using exactly the same therapy regimens, Dow et aL (1983) found that both types of implant were equally effective in reducing the severity of psychological, 
